Possible factors affecting response to intravesical bacillus Calmette- Guerin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: A multivariate analysis

International Urology and Nephrology

Volumn 30, Issue 6, 1998, Pages 713-722

  Takashi, M ^a   Katsuno, S ^a   Yuba, H ^a   Ohshima, S ^a   Wakai, K ^a   Ohno, Y ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CYSTECTOMY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; TREATMENT OUTCOME;

EID: 0032451512     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02564859     Document Type: Article

References (35)

1. Prout, G. R. Jr., Griffin, P. P., Daly, J. J., Heney, N. M.: Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer, 52, 524 (1983).
2. Lamm, D. L.: Superficial bladder cancer: Carcinoma in situ. Ural. Clin. North Am, 19, 499 (1992).
3. Weinstein, R. S., Miller, A. W. III., Pauli, B. U.: Carcinoma in situ: Comments on the pathobiology of a paradox. Urol. Clin. North Am., 7, 523 (1980).
4. Utz, D. C., Hanash, K. A., Farrow, G. M,: The plight of the patient with carcinoma in situ of the bladder. J. Urol., 103, 160 (1970).
5. Morales, A., Eidinger, D., Bruce, A. W.: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumours. J. Urol., 116, 180 (1976).
6. Brosman, S. A.: The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ. J. Urol., 134, 36 (1985).
7. deKernion, J. B., Huang, M., Lindner, A., Smith, R. B., Kaufman, J. J.: The management of superficial bladder tumours and carcinoma in situ with intravesical bacillus Calmette-Guérin. J Urol., 133, 598 (1985).
8. Herr, H. W., Pinsky, C. M., Whitmore, W. F, Jr., Sogani, P. C., Oettgen, H. F., Melamed, M. R.: Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol., 135, 265 (1986).
9. Takashi, M., Kondo, A., Nakano, Y., Takagi, Y., Sakata, T., Miyake, K.: Total cystectomy after intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer: Experience in Japan. Int. Urol., Nephrol., 26, 33 (1994).
10. Akaza, H., Hinotsu, S., Aso, Y., Kakizoe, T., Koiso, K.: Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer, 75, 552 (1995).
11. Sinka, T., Matsumoto, M., Ogura, H., Hirano, A., Ohkawa, T.: Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: A long term follow-up. Int. J. Urol., 4, 139 (1997).
12. Takashi, M., Shimoji, T., Murase, T., Sakata, T., Sobajima, T., Suzuki, Y.: Intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder. Int. Urol. Nephrol , 29, 557 (1997).
13. Farrow, G. M.: Pathology of carcinoma in situ of the urinary bladder and related lesions. J. Cell Biochem. (Suppl.), 16, 39 (1992).
14. Union Internationale Contre le Cancer: TNM Classification of Malignant Tumours. Union Internationale Contre le Cancer, Geneva 1974.
15. Koss, L. G.: Tumors of the Urinary Bladder. Atlas of Tumor Pathology. 2nd ser., fasc. 11. Armed Forces Institute of Pathology, Washington, D.C. 1975.
16. Kaplan, E. L., Meier, P.: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457 (1958).
17. Gehan, E. A.: A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika, 52, 203 (1965).
18. Walker, S. H., Duncan, D. B.: Estimation of the probability of an event as a function of several independent variables. Biometrika, 54, 167 (1967).
19. Hudson, M. A., Herr, H. W., Carcinoma in situ of the bladder. J. Urol., 153, 564 (1995).
20. Coplen, D. E., Marcus, M. D., Myers, J. A., Ratliff, T. L., Catalona, W. J.: Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: Analysis of possible predictors of response free of tumor. J. Urol., 144, 652 (1990).
21. Merz, V. W., Kraft, M. R., Ackermann, D. K., Zingg, E. J., Studer, U. E.: Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder. Br. J. Urol., 75, 180 (1995).
22. Ratliff, T. L., Kavoussi, L. R., Catalona, W. J.: Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J. Urol., 139, 410 (1988).
23. Kavoussi, L. R., Brown, E. J., Ritchey, J. K., Ratliff, T. L.: Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa: Requirement for the expression of an antitumor response. J. Clin. Invest., 85, 62 (1990).
24. Humphries, M. J., Obara, M., Olden, K., Yamada, K. M.: Role of fibronectin in adhesion, migration, and metastasis. Cancer Invest., 7, 373 (1989).
25. Murasko, D. M., Nelson, B. J., Silver, R., Matour, D., Kaye, D.: Immunologic response in an elderly population with a mean age of 85. Am. J. Med., 81, 612 (1986).
26. Miller, R. A.: The aging immune system: Primer and prospectus. Science, 273, 70 (1996).
27. Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L., Catalona, W. J.: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150, 1018 (1993).
28. Thanhäuser, A., Böhle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H.-D., Ulmer, A. J.: The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol. Immunother., 40, 103 (1995).
29. Van Gils-Gielen, R. J. M., Debruyne, F. M. J., Witjes, W. P. J., Witjes, J. A., Caris, C. T. M., Oosterhof, G. O. N.: Risk factors in carcinoma in situ of the urinary bladder. Urology, 45, 581 (1995).
30. Steg, A., Belas, M., Leleu, C., Boccon-Gibod, L.: Intravesical BCG therapy in patients with superficial bladder tumors. In: Debruyne, F. M. J., Denis, L., van der Meijden, A. P. M. (eds): EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer. Alan R. Liss, New York 1989, pp. 153-160.
31. Sekine, H., Fukui, I., Yamada, T., Kojima, S., Ohshima, H.: Histological grading of carcinoma in situ of the bladder: Its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy. J. Urol., 155, 94 (1996).
32. Takashi, M., Wakai, K., Ohno, Y., Murase, T., Miyake, K.: Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer. Int. Urol. Nephrol., 27, 723 (1995).
33. Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. C., Freedman, B. D., Melamed, M. R., Whitmore, W. F. Jr.: Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol., 6, 1450 (1980).
34. Norming, U., Tribukait, B., Gustafson, H., Nyman, C. R., Wang, N., Wijkström, H.: Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: A study of 63 patients with grade 3 lesions. J. Urol., 147, 11 (1992).
35. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z., Sheinfeld, J., Fair, W. R., Herr, H. W., Reuter, V. E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152, 388 (1994).